Scientific Reports (May 2023)

External validation of a radiomic signature to predict p16 (HPV) status from standard CT images of anal cancer patients

  • Ralph T. H. Leijenaar,
  • Sean Walsh,
  • Akshayaa Vaidyanathan,
  • Lorenzo Aliboni,
  • Victoria Lopez Sanchez,
  • Michelle Leech,
  • Ronan Joyce,
  • Charles Gillham,
  • Frédéric Kridelka,
  • Roland Hustinx,
  • Denis Danthine,
  • Mariaelena Occhipinti,
  • Wim Vos,
  • Julien Guiot,
  • Philippe Lambin,
  • Pierre Lovinfosse

DOI
https://doi.org/10.1038/s41598-023-34162-3
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 7

Abstract

Read online

Abstract The paper deals with the evaluation of the performance of an existing and previously validated CT based radiomic signature, developed in oropharyngeal cancer to predict human papillomavirus (HPV) status, in the context of anal cancer. For the validation in anal cancer, a dataset of 59 patients coming from two different centers was collected. The primary endpoint was HPV status according to p16 immunohistochemistry. Predefined statistical tests were performed to evaluate the performance of the model. The AUC obtained here in anal cancer is 0.68 [95% CI (0.32–1.00)] with F1 score of 0.78. This signature is TRIPOD level 4 (57%) with an RQS of 61%. This study provides proof of concept that this radiomic signature has the potential to identify a clinically relevant molecular phenotype (i.e., the HPV-ness) across multiple cancers and demonstrates potential for this radiomic signature as a CT imaging biomarker of p16 status.